Sectors & IndustriesHealthcareDrug Manufacturers - Specialty & Generic
Best Pharmaceutical Stocks to Buy Now (2025)
Top pharmaceutical stocks in 2025 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best pharmaceutical stocks to buy now. Learn More.

Industry: Drug Manufacturers - Spec...
B
Pharmaceutical is Zen Rated B and is the 36th ranked industry out of 145 stock market industries
Learn how the Zen Ratings work
Ticker
Company
Zen Rating
Sentiment
Market Cap
Shares
Institutional %
Insider %
Net Insider (L12M)
Net Insider (L3M)
AMRX
AMNEAL PHARMACEUTICALS INC
$3.14B314,079,30927.53%72.47%Net SellingNet Selling
INDV
INDIVIOR PLC
$2.90B124,769,82085.67%0.00%
ANIP
ANI PHARMACEUTICALS INC
$2.12B21,661,93529.08%70.92%Net SellingNet Selling
IRWD
IRONWOOD PHARMACEUTICALS INC
$212.79M162,434,13069.14%30.86%Net SellingNet Selling
SIGA
SIGA TECHNOLOGIES INC
$638.73M71,606,00335.68%64.32%Net SellingNet Selling
PAHC
PHIBRO ANIMAL HEALTH CORP
$1.61B40,533,60844.48%55.52%Net SellingNet Selling
COLL
COLLEGIUM PHARMACEUTICAL INC
$1.20B32,142,19251.01%48.99%Net SellingNet Selling
AVDL
AVADEL PHARMACEUTICALS PLC
$1.50B97,097,63983.77%13.63%Net Buying
NBIX
NEUROCRINE BIOSCIENCES INC
$14.07B99,181,51071.13%28.87%Net SellingNet Buying
KMDA
KAMADA LTD
$403.69M57,505,03110.05%0.00%
VTRS
VIATRIS INC
$11.61B1,165,872,12782.06%17.94%Net SellingNet Buying
ELAN
ELANCO ANIMAL HEALTH INC
$9.21B496,813,70291.28%8.72%Net SellingNet Selling
TEVA
TEVA PHARMACEUTICAL INDUSTRIES LTD
$22.86B1,147,150,91762.80%0.79%Net SellingNet Selling
CPIX
CUMBERLAND PHARMACEUTICALS INC
$51.47M14,961,13724.61%55.84%Net BuyingNet Buying
DVAX
DYNAVAX TECHNOLOGIES CORP
$1.13B120,080,65063.57%36.43%Net SellingNet Selling
BHC
BAUSCH HEALTH COMPANIES INC
$2.68B369,790,31951.69%48.31%Net BuyingNet Buying
AYTU
AYTU BIOPHARMA INC
$14.56M6,170,24610.39%89.61%Net Buying
SUPN
SUPERNUS PHARMACEUTICALS INC
$2.55B56,073,08846.27%53.73%Net BuyingNet Buying
PCRX
PACIRA BIOSCIENCES INC
$1.22B44,932,72168.66%31.34%Net SellingNet Selling
PRGO
PERRIGO CO PLC
$3.06B137,582,81463.15%36.85%Net BuyingNet Buying
HCM
HUTCHMED (CHINA) LTD
$3.13B871,601,0950.70%0.00%
ZTS
ZOETIS INC
$65.68B443,183,47294.25%5.75%Net SellingNet Selling
ETON
ETON PHARMACEUTICALS INC
$473.33M26,817,53561.71%33.14%Net SellingNet Selling
ESPR
ESPERION THERAPEUTICS INC
$572.61M201,622,82548.72%20.33%Net SellingNet Selling
HROW
HARROW INC
$1.46B37,002,13628.63%71.37%Net SellingNet Buying
TAK
TAKEDA PHARMACEUTICAL CO LTD
$47.17B1,561,993,8534.99%0.00%
HLN
HALEON PLC
$44.56B9,083,725,9196.49%0.00%
AMPH
AMPHASTAR PHARMACEUTICALS INC
$1.32B47,139,08548.24%51.76%Net BuyingNet Selling
ALKS
ALKERMES PLC
$4.45B165,077,97993.21%6.79%Net SellingNet Selling
EBS
EMERGENT BIOSOLUTIONS INC
$441.82M54,277,82744.23%55.77%Net SellingNet Selling
DERM
JOURNEY MEDICAL CORP
$173.33M24,378,18626.64%34.64%Net BuyingNet Buying
TKNO
ALPHA TEKNOVA INC
$237.81M53,440,81014.34%64.16%Net SellingNet Selling
BGM
BGM GROUP LTD
$53.35M7,226,4801.83%0.00%
ALVO
ALVOTECH
$2.50B311,601,1545.53%0.00%
CTOR
CITIUS ONCOLOGY INC
$149.69M78,370,5840.29%88.17%
QNTM
QUANTUM BIOPHARMA LTD
$59.77M3,468,6913.36%0.00%
LFCR
LIFECORE BIOMEDICAL INC
$278.43M37,025,33148.98%51.02%Net BuyingNet Selling
EVO
EVOTEC SE
$1.23B177,766,5415.43%0.00%
PBH
PRESTIGE CONSUMER HEALTHCARE INC
$3.13B49,414,70769.27%30.73%Net Selling
RGC
REGENCELL BIOSCIENCE HOLDINGS LTD
$7.27B494,488,9080.14%0.00%
LNTH
LANTHEUS HOLDINGS INC
$3.60B67,994,14954.77%45.23%Net SellingNet Selling
ORGO
ORGANOGENESIS HOLDINGS INC
$625.39M126,853,5366.70%93.30%Net SellingNet Buying
IXHL
INCANNEX HEALTHCARE INC
$16.10M29,433,7983.47%15.45%
EVOK
EVOKE PHARMA INC
$8.06M1,558,4651.93%98.07%Net Buying
RDY
DR REDDYS LABORATORIES LTD
$12.23B834,455,36512.87%0.00%
RMTI
ROCKWELL MEDICAL INC
$55.78M34,430,35214.01%85.99%Net SellingNet Selling
CRON
CRONOS GROUP INC
$975.11M385,419,02112.30%48.73%Net Selling
OGI
ORGANIGRAM GLOBAL INC
$222.48M134,022,1675.45%0.00%
CRDL
CARDIOL THERAPEUTICS INC
$88.46M82,674,7257.82%0.00%
AQST
AQUESTIVE THERAPEUTICS INC
$503.60M99,723,63547.76%7.74%Net SellingNet Selling
CGC
CANOPY GROWTH CORP
$253.71M185,192,2109.24%58.14%Net SellingNet Selling
KALA
KALA BIO INC
$120.14M6,452,3986.74%93.26%Net BuyingNet Selling
EOLS
EVOLUS INC
$465.09M64,685,41976.74%23.26%Net SellingNet Buying
BIOA
BIOAGE LABS INC
$172.08M35,850,03757.79%24.78%Net Buying
ACB
AURORA CANNABIS INC
$273.95M56,252,66010.29%0.00%
SHPH
SHUTTLE PHARMACEUTICALS HOLDINGS INC
$3.84M1,070,7730.05%99.95%
TLRY
TILRAY BRANDS INC
$1.23B1,100,530,0999.34%1.87%Net BuyingNet Buying
AKAN
AKANDA CORP
$2.35M655,1464.56%0.00%
YCBD
CBDMD INC
$6.06M8,912,9591.16%98.84%
PRFX
PAINREFORM LTD
$2.09M1,471,4121.36%0.00%
TXMD
THERAPEUTICSMD INC
$12.85M11,574,3623.56%96.44%Net Buying
SNOA
SONOMA PHARMACEUTICALS INC
$7.34M1,642,7652.17%97.83%
CPHI
CHINA PHARMA HOLDINGS INC
$5.94M3,262,0020.23%99.77%
TLPH
TALPHERA INC
$19.29M20,522,65511.00%89.00%Net Buying
BFRI
BIOFRONTERA INC
$8.97M10,668,44219.15%5.14%
ASRT
ASSERTIO HOLDINGS INC
$78.24M96,239,62526.03%21.24%Net Selling
SXTC
CHINA SXT PHARMACEUTICALS INC
$27.25M13,763,2680.56%0.00%
IMCC
IM CANNABIS CORP
$7.97M4,044,8125.59%0.00%
APUS
APIMEDS PHARMACEUTICALS US INC
$26.16M12,575,9830.23%57.97%Net Buying
RDHL
REDHILL BIOPHARMA LTD
$0.0012,899,831,0000.00%0.00%
UPC
UNIVERSE PHARMACEUTICALS INC
$2.26M563,3380.00%0.00%
INCR
INTERCURE LTD
$74.05M47,162,7135.29%0.00%
FLGC
FLORA GROWTH CORP
$14.03M578,6835.72%94.28%
SBFM
SUNSHINE BIOPHARMA INC
$6.82M4,555,9452.85%87.90%
SCYX
SCYNEXIS INC
$46.96M41,924,94126.49%21.48%Net Buying
GELS
GELTEQ LTD
$15.10M9,438,0751.12%0.00%

Pharmaceutical Stocks FAQ

What are the best pharmaceutical stocks to buy right now in Sep 2025?

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best pharma stocks to buy right now are:

1. Amneal Pharmaceuticals (NASDAQ:AMRX)


Amneal Pharmaceuticals (NASDAQ:AMRX) is the #1 top pharmaceutical stock out of 76 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Amneal Pharmaceuticals (NASDAQ:AMRX) is: Value: B, Growth: B, Momentum: C, Sentiment: A, Safety: B, Financials: B, and AI: C.

Amneal Pharmaceuticals (NASDAQ:AMRX) has a Due Diligence Score of 37, which is 10 points higher than the pharmaceutical industry average of 27.

AMRX passed 12 out of 33 due diligence checks and has average fundamentals. Amneal Pharmaceuticals has seen its stock return 18.06% over the past year, overperforming other pharmaceutical stocks by 65 percentage points.

2. Indivior (NASDAQ:INDV)


Indivior (NASDAQ:INDV) is the #2 top pharmaceutical stock out of 76 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Indivior (NASDAQ:INDV) is: Value: B, Growth: C, Momentum: B, Sentiment: A, Safety: C, Financials: B, and AI: C.

Indivior (NASDAQ:INDV) has a Due Diligence Score of 26, which is -1 points lower than the pharmaceutical industry average of 27. Although this number is below the industry average, our proven quant model rates INDV as a "A".

INDV passed 8 out of 33 due diligence checks and has average fundamentals. Indivior has seen its stock return 141.27% over the past year, overperforming other pharmaceutical stocks by 188 percentage points.

Indivior has an average 1 year price target of $27.33, an upside of 17.76% from Indivior's current stock price of $23.21.

Indivior stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 3 analysts covering Indivior, 33.33% have issued a Strong Buy rating, 66.67% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Ani Pharmaceuticals (NASDAQ:ANIP)


Ani Pharmaceuticals (NASDAQ:ANIP) is the #3 top pharmaceutical stock out of 76 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Ani Pharmaceuticals (NASDAQ:ANIP) is: Value: C, Growth: A, Momentum: C, Sentiment: A, Safety: C, Financials: C, and AI: B.

Ani Pharmaceuticals (NASDAQ:ANIP) has a Due Diligence Score of 22, which is -5 points lower than the pharmaceutical industry average of 27. Although this number is below the industry average, our proven quant model rates ANIP as a "A".

ANIP passed 8 out of 33 due diligence checks and has weak fundamentals. Ani Pharmaceuticals has seen its stock return 74.02% over the past year, overperforming other pharmaceutical stocks by 121 percentage points.

Ani Pharmaceuticals has an average 1 year price target of $91.60, a downside of -6.25% from Ani Pharmaceuticals's current stock price of $97.71.

Ani Pharmaceuticals stock has a consensus Buy recommendation according to Wall Street analysts. Of the 5 analysts covering Ani Pharmaceuticals, 40% have issued a Strong Buy rating, 40% have issued a Buy, 20% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the pharmaceutical stocks with highest dividends?

Out of 6 pharmaceutical stocks that have issued dividends in the past year, the 3 pharmaceutical stocks with the highest dividend yields are:

1. Viatris (NASDAQ:VTRS)


Viatris (NASDAQ:VTRS) has an annual dividend yield of 4.82%, which is 3 percentage points higher than the pharmaceutical industry average of 2.26%. Viatris's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Viatris's dividend has shown consistent growth over the last 10 years.

Viatris's dividend payout ratio of -16.6% indicates that its high dividend yield might not be sustainable for the long-term.

2. Perrigo Co (NYSE:PRGO)


Perrigo Co (NYSE:PRGO) has an annual dividend yield of 3.84%, which is 2 percentage points higher than the pharmaceutical industry average of 2.26%. Perrigo Co's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Perrigo Co's dividend has shown consistent growth over the last 10 years.

Perrigo Co's dividend payout ratio of -195.2% indicates that its high dividend yield might not be sustainable for the long-term.

3. Kamada (NASDAQ:KMDA)


Kamada (NASDAQ:KMDA) has an annual dividend yield of 2.85%, which is 1 percentage points higher than the pharmaceutical industry average of 2.26%.

Kamada's dividend payout ratio of 60.6% indicates that its dividend yield is sustainable for the long-term.

Why are pharmaceutical stocks down?

Pharmaceutical stocks were down -1.02% in the last day, and up 0.12% over the last week.

We couldn't find a catalyst for why pharmaceutical stocks are down.

What are the most undervalued pharmaceutical stocks?

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued pharmaceutical stocks right now are:

1. Bausch Health Companies (NYSE:BHC)


Bausch Health Companies (NYSE:BHC) is the most undervalued pharmaceutical stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Bausch Health Companies has a valuation score of 57, which is 37 points higher than the pharmaceutical industry average of 20. It passed 4 out of 7 valuation due diligence checks.

Bausch Health Companies's stock has gained 15.24% in the past year. It has overperformed other stocks in the pharmaceutical industry by 62 percentage points.

2. Emergent Biosolutions (NYSE:EBS)


Emergent Biosolutions (NYSE:EBS) is the second most undervalued pharmaceutical stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Emergent Biosolutions has a valuation score of 14, which is -6 points higher than the pharmaceutical industry average of 20. It passed 1 out of 7 valuation due diligence checks. Although this number is below the industry average, our proven quant model rates EBS a Valuation Rating of "A".

Emergent Biosolutions's stock has gained 6.68% in the past year. It has overperformed other stocks in the pharmaceutical industry by 53 percentage points.

3. Siga Technologies (NASDAQ:SIGA)


Siga Technologies (NASDAQ:SIGA) is the third most undervalued pharmaceutical stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Siga Technologies has a valuation score of 86, which is 66 points higher than the pharmaceutical industry average of 20. It passed 6 out of 7 valuation due diligence checks.

Siga Technologies's stock has gained 13.34% in the past year. It has overperformed other stocks in the pharmaceutical industry by 60 percentage points.

Are pharmaceutical stocks a good buy now?

48.78% of pharmaceutical stocks rated by analysts are a buy right now. On average, analysts expect pharmaceutical stocks to rise by 31.3% over the next year.

19.3% of pharmaceutical stocks have a Zen Rating of A (Strong Buy), 15.79% of pharmaceutical stocks are rated B (Buy), 47.37% are rated C (Hold), 15.79% are rated D (Sell), and 1.75% are rated F (Strong Sell).

What is the average p/e ratio of the drug manufacturers - specialty & generic industry?

The average P/E ratio of the drug manufacturers - specialty & generic industry is -22.23x.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.